https://orcid.org/0000-0002-0886-9769
References
- Vamathevan J, Clark D, Czodrowski P, et al., Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477.
- Bhinder B, Gilvary C, Madhukar NS, et al. Artificial intelligence in cancer research and precision medicine. Cancer Discov. 2021;11(4):900–915.
- Roberts M, Driggs D, Thorpe M, et al. Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans. Nat Mach Intell. 2021;3(3):199–217.
- Muratov EN, Amaro R, Andrade CH, et al. A critical overview of computational approaches employed for COVID-19 drug discovery. Chem Soc Rev. 2021;50(16):9121–9151.
- Walsh I, Fishman D, Garcia-Gasulla D, et al. DOME: recommendations for supervised machine learning validation in biology. Nat Methods. 2021;18(10):1122–1127.
- Heil BJ, Hoffman MM, Markowetz F, et al. Reproducibility standards for machine learning in the life sciences. Nat Methods. 2021;18(10):1132–1135.
- Tanoli Z, Vähä-Koskela M, Aittokallio T. Artificial intelligence, machine learning, and drug repurposing in cancer. Expert Opin Drug Discov. 2021;16(9):977–989.
- Ballester PJ, Stevens R, Haibe-Kains B, et al., Artificial intelligence for drug response prediction in disease models. Brief Bioinform. 23(1): bbab450. 2022.
- Julkunen H, Cichonska A, Gautam P, et al. Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects. Nat Commun. 2020;11(1):6136.
- White J, Schiffer JT, Bender R, et al. Drug combinations as a first line of defense against coronaviruses and other emerging viruses. mBio. 2021;12(6):e0334721.
- Attwood MM, Fabbro D, Sokolov AV, et al. Trends in kinase drug discovery: targets, indications and inhibitor design. Nat Rev Drug Discov. 2021;20(11):839–861.
- Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551–569.
- Ianevski A, Lahtela J, Javarappa KK, et al., Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Sci Adv. 7(8): eabe4038. 2021.
- Avila Cobos F, Alquicira-Hernandez J, Powell JE, et al. Benchmarking of cell type deconvolution pipelines for transcriptomics data. Nat Commun. 2020;11(1):5650.
- Guinney J, Saez-Rodriguez J. Alternative models for sharing confidential biomedical data. Nat Biotechnol. 2018;36(5):391–392.
- Jiménez-Luna J, Grisoni F, and Schneider G. Drug discovery with explainable artificial intelligence. Nat Mach Intell. 2020;2(10):573–584.